Osteoblasts and Bone Formation

Understanding the differentiation sequence explains marker expression and therapeutic targets. It runs in five stages:

1. Mesenchymal stem cell (MSC) - a multipotent progenitor, present in bone marrow and periosteum, that can differentiate into osteoblasts, chondrocytes, adipocytes or myoblasts
2. Osteoprogenitor - committed to the osteoblast lineage and expressing Runx2; it can still proliferate and has no alkaline phosphatase yet
3. Preosteoblast - expresses osterix (Sp7, downstream of Runx2) and begins to express alkaline phosphatase as proliferation slows
4. Mature osteoblast - a cuboidal cell on the bone surface in active matrix synthesis, with high alkaline phosphatase activity, secreting type I collagen and non-collagenous proteins (osteocalcin, osteopontin)
5. Terminal fate - osteocyte, bone lining cell or apoptosis (see Osteoblast Terminal Differentiation)

View larger

Two lineages, one surface. Osteoblasts and osteoclasts come from separate lineages that meet at the bone surface: osteoblasts descend from mesenchymal stem cells, while osteoclasts derive from the monocyte-macrophage line.

View larger

Runx2 is the master switch. Runx2 (Cbfa1) is the master transcription factor for osteoblast differentiation, and it is non-redundant: no other gene can compensate for its loss. Runx2 knockout mice die at birth with a complete absence of bone: osteoblast maturation arrests, and "no osteoblasts, no bone" is shorthand for that arrest (Komori). In humans, RUNX2 haploinsufficiency causes cleidocranial dysplasia.

What it switches on. Runx2 activates the downstream osteoblast genes Col1a1, alkaline phosphatase and osteocalcin. The protein has two domains, a DNA-binding Runt domain and a transactivation domain, and the gene lies on chromosome 6.

The cascade. The transcription factors are hierarchical: Runx2 is required first, then activates osterix (Sp7), which allows full osteoblast maturation.

Wnt/β-catenin is the primary anabolic pathway. Named from the Drosophila wingless gene, Wnt signalling promotes osteoblast differentiation and function and inhibits osteoblast apoptosis. Wnt ligands bind Frizzled receptors with the LRP5/6 co-receptors; β-catenin is stabilised, which prevents its degradation, and it translocates to the nucleus to drive TCF/LEF transcription.

The brakes on Wnt. Sclerostin (the SOST gene product, secreted by osteocytes) and Dickkopf-1 (DKK1) inhibit the pathway by binding and blocking LRP5/6. Anti-sclerostin antibodies such as romosozumab remove that brake and are anabolic bone agents.

BMP signalling. BMP-2 and BMP-7 are potent osteoinductive factors that promote osteoblast differentiation from MSCs. They bind the BMPR-IA/IB receptors, and Smad1/5/8 phosphorylation then activates Runx2. They are used clinically for nonunion and spinal fusion, BMP-2 as Infuse for spinal fusion and tibial nonunion.

Osteoid. Osteoblasts secrete both collagen and non-collagenous proteins to form osteoid, the unmineralised matrix. Type I collagen makes up 90% of the organic matrix and the non-collagenous proteins the remaining 10%.

Making type I collagen. Synthesis runs from the cell to the cross-linked fibril:

1. Intracellular procollagen synthesis (pro-α1 and pro-α2 chains)
2. Post-translational modification: hydroxylation, which requires vitamin C, and glycosylation
3. Triple-helix formation from two α1(I) chains and one α2(I) chain
4. Secretion of procollagen into the osteoid
5. Extracellular processing, as proteases cleave the N- and C-propeptides
6. Fibril assembly, as tropocollagen self-assembles with a 67 nm periodicity
7. Cross-linking by lysyl oxidase, which creates pyridinoline and deoxypyridinoline cross-links

The non-collagenous proteins. They bind calcium, mediate cell adhesion and regulate crystal formation:

• Osteocalcin - vitamin K-dependent; binds calcium and regulates mineralisation
• Osteopontin - cell adhesion; regulates crystal growth
• Bone sialoprotein (BSP) - nucleates hydroxyapatite crystal formation
• Osteonectin (SPARC) - binds collagen and calcium, linking the organic and mineral phases

Alkaline phosphatase is the key enzyme. Pyrophosphate (PPi) is a mineralisation inhibitor. Alkaline phosphatase (ALP), the osteoblast marker enzyme, hydrolyses it, raising the local phosphate concentration and allowing hydroxyapatite crystals to form. Serum ALP reflects osteoblast activity.

The sequence. Mineral is not deposited at once: the lag allows time for matrix maturation and cross-linking first.

1. Osteoid deposition - unmineralised matrix laid down by osteoblasts
2. Maturation period - 10-14 days, with an osteoid seam 10-15 micrometres thick
3. Matrix vesicles - membrane-bound vesicles, rich in ALP and calcium, bud from osteoblasts
4. Nucleation - the first hydroxyapatite crystals form in the matrix vesicles
5. Crystal growth - crystals propagate into the collagen fibrils, at the gap zones
6. Primary mineralisation - a rapid phase, reaching 70% of final mineral content in days
7. Secondary mineralisation - a slow phase, reaching 95% over months

The markers reflect different stages of osteoblast differentiation and function, and only some of them are clinical tests.

Systemic factors coordinate bone formation with whole-body calcium and phosphate homeostasis.

Beyond the classical hormones. Osteoblast activity is modulated by receptors well beyond the classical bone hormones, including FSH, TSH and adrenergic signalling. Common variants in these receptors tip the formation-resorption balance toward resorption, which is part of why bone loss accelerates around the menopause independently of oestrogen alone.

View larger

Local factors provide paracrine and autocrine regulation of bone formation. The BMPs are covered under Signalling Pathways in Osteoblast Differentiation; the others are:

• TGF-β - abundant in bone matrix and released during resorption; promotes osteoprogenitor proliferation but inhibits terminal differentiation
• IGF-I and IGF-II - produced by osteoblasts and stored in bone matrix; stimulate osteoblast proliferation and collagen synthesis
• Prostaglandin E2 (PGE2) - increases cAMP in osteoblasts; biphasic, anabolic at low dose and catabolic at high dose

Wolff's law, cell by cell. Mechanical regulation allows bone to adapt to functional demands. These six steps, with the osteocyte as mechanosensor, are the cellular mechanism of Wolff's law (bone adapts to mechanical stress):

1. Mechanical strain deforms the bone matrix
2. Fluid flows in the osteocyte canaliculi (the lacunar-canalicular system)
3. Osteocytes sense the fluid shear stress through the primary cilium and integrins
4. Sclerostin falls, as SOST gene expression is reduced
5. Wnt signalling rises, with less sclerostin inhibition of LRP5/6
6. Osteoblast activity, and so bone formation, increases

Unloading runs it in reverse. Sclerostin rises and bone formation is suppressed, which explains bone loss in immobilised patients and astronauts. In practice, exercise and loading increase bone mass, immobilisation and unloading (bed rest, spaceflight) decrease it, and vibration therapy may have anabolic effects.

Osteoblasts control osteoclasts. The osteoblast/osteocyte lineage is the master controller of osteoclast formation. Osteoblasts and osteocytes express RANKL (receptor activator of NF-κB ligand), which binds RANK on osteoclast precursors and, together with M-CSF, drives their differentiation and activation. Osteocytes are now recognised as a dominant source of RANKL in adult bone remodelling.

The decoy. The same cells secrete osteoprotegerin (OPG), a soluble decoy receptor that binds RANKL and prevents it engaging RANK. The RANKL:OPG ratio therefore sets the resorptive tone: a high ratio favours resorption, a low ratio favours formation.

Coupling. Resorption and formation are linked, partly via matrix-derived factors (TGF-β, IGF-1) released during resorption that recruit osteoblasts. In each cycle osteoclasts excavate a resorption cavity, reversal cells prepare the surface, osteoblasts fill it with osteoid, and mineralisation completes before the surface returns to rest. Formation always follows resorption, which is why purely antiresorptive drugs cannot add much new bone.

View larger

The drug target. The same axis is the target of denosumab, an anti-RANKL antibody and the antiresorptive mirror to the osteoblast-stimulating anabolic agents.